667, L.P. resale reported for TARA (NASDAQ: TARA) — 26,755 shares

Rhea-AI Filing Summary

667, L.P. reported the sale of 26,755 shares of Common Stock. The Form 144 excerpt lists a sale date of 02/24/2026 and a reported value of $161,584.00.

The filing names Canaccord Genuity LLC as a broker and includes additional trade dates of 12/08/2025 and 02/25/2026 in the securities table.

Insights

Corporate Governance Analyst

Routine Form 144 reporting a resale by an affiliated holder.

The excerpt documents a resale by 667, L.P. of 26,755 shares on 02/24/2026, with a reported value of $161,584.00. The broker listed is Canaccord Genuity LLC.

This filing appears administrative in nature and does not by itself change governance or capital structure. Subsequent filings could show further holder activity or aggregated disposition details.

FAQ

What does the TARA Form 144 report?

The filing reports a resale of 26,755 common shares on 02/24/2026. The excerpt shows a reported value of $161,584.00 and names Canaccord Genuity LLC as a broker.

Who executed the sale reported in the TARA Form 144?

The sale is reported by 667, L.P., which sold 26,755 shares on 02/24/2026. The broker indicated in the excerpt is Canaccord Genuity LLC.

When were the securities sold according to the excerpt?

The excerpt lists a sale date of 02/24/2026 for 26,755 shares. It also shows related trade dates of 12/08/2025 and 02/25/2026 in the securities table.

How much value was reported for the shares sold in the TARA filing?

The excerpt reports a total of $161,584.00 alongside the 26,755 shares sold on 02/24/2026. The filing ties that dollar amount to the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 07:58 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001551139
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Protara Therapeutics, Inc.
SEC File Number	001-36694
Address of Issuer	345 Park Avenue South Third Floor New York NEW YORK 10010
Phone	646-844-0337
Name of Person for Whose Account the Securities are To Be Sold	667, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Canaccord Genuity LLC 99 High Street, Suite 1200 Boston MA 02110	78716	457046.00	53587260	02/25/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	12/08/2025	See Remark 2	Underwriter			2009	12/08/2025	Cash
Common Stock	02/25/2026	See Remark 3	Broker			76707	02/25/2026	See Remark 3

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
667, L.P. 860 Washington Street, 3rd Floor New York NY 10014	Common Stock	02/24/2026	26755	161584.00

144: Remarks and Signature

Remarks	(1) 667, L.P. is affiliated with Baker Brothers Life Sciences, L.P. Baker Bros. Advisors LP serves as the investment adviser to 667, L.P. and Baker Brothers Life Sciences, L.P. Baker Brothers Life Sciences, L.P. is filing separately for the sale of 947,479 shares of common stock ("Common Stock") of Protara Therapeutics, Inc. (the "Issuer"), which along with the reported sales in this form by 667, L.P. totals 1,026,195 shares of Common Stock. (2) Common Stock acquired in underwritten public offering. (3) Common Stock borrowed from broker.
Date of Notice	02/25/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	By: BAKER BROS. ADVISORS LP, mgmt company and IA to 667, L.P., /s/ Scott L. Lessing, President
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)